COMP <GO>
THC vs LLY // ALTMAN Z-SCORE & DEBT/EQUITY
Tenet Healthcare Corporation (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: THC 4
— LLY 11
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: LLY
LAST: $273.25 (+0.99%) • MKT CAP: $21.79B
balance-sheet
2.08
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
balance-sheet
9.29
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (THC VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | THC | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 83.64% | -42.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 27.60% | 32.36% | -4.76 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.3x | 36.4x | -30.12 | THC | /valuation <GO> |
| Free Cash Flow Yield | 11.61% | 2.30% | +9.31 | THC | /fcf-yield <GO> |
| Operating Margin | 16.50% | 40.21% | -23.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | 11.10% | 31.90% | -20.80 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 3.10% | 45.51% | -42.41 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 2.08 | 9.29 | -7.21 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.77% | +0.03 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.2 | 77.9 | -19.72 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | 0.51 | +0.46 | THC | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.6x | 26.3x | -17.65 | THC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $21.79B | $1.33T | -$1.31T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | THC REV | LLY REV | THC GROSS % | LLY GROSS % | THC FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $21.31B | $65.18B | 44.0% | 83.0% | $2.53B | $16.81B |
| FY 2024 | $20.68B | $45.04B | 44.0% | 81.3% | $1.12B | $8.82B |
| FY 2023 | $20.56B | $34.12B | 44.0% | 79.3% | $1.45B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
THC // BETA 0.97
LLY // BETA 0.51